Johnson & Johnson’s new sponsorship of “Give a Spit for Cancer” features comedian Hannibal Buress in the ongoing drive to register potential bone marrow…
In 2016, many pharma marketers embraced disease awareness and charitable causes to drive better consumer engagement across social networks, according to a new…
The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…
The fast and furious two-day Round 2 match-ups carved the pharma ad field down to 16, with disease awareness emerging as a winning theme.
It looks like we might be in for another big patent brawl between Sanofi and Regeneron on one side and Amgen on the other.
Thanks to the FDA, competition for Valeant's lead drug may be on its way sooner than the embattled drugmaker would like.
How would a “competitive bidding process” for drugs work? We may soon find out, if President Trump gets his way with the Republican healthcare bill.
After an upswing in pharma's global reputation in 2015, its standing among patient groups has swung the other way—again.
Pressure from pharmacy benefit managers and increased competition among drugmakers are taking a big bite out of Eli Lilly's list-price hikes.
Novartis has some new data in hand that could set psoriasis med Cosentyx apart from its new competitors—big-time.
China's Food and Drug Administration proposed changes to its foreign drug approval rules in a bid to speed new, innovative meds to market.